Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.788
-0.060 (-1.56%)
At close: Apr 14, 2026, 4:00 PM EDT
3.800
+0.012 (0.32%)
After-hours: Apr 14, 2026, 7:05 PM EDT
Exicure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
24.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | - |
| Dec 31, 2021 | -483.00K | -17.10M | - |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | 1.30M | 1.18M | 998.31% |
| Dec 31, 2018 | 118.00K | -9.60M | -98.79% |
| Dec 31, 2017 | 9.72M | 8.68M | 838.13% |
| Dec 31, 2016 | 1.04M | -1.35M | -56.62% |
| Dec 31, 2015 | 2.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Vistagen Therapeutics | 789.00K |
| Lexaria Bioscience | 522.00K |
| Outlook Therapeutics | 205.70K |
| Serina Therapeutics | 130.00K |
XCUR News
- 12 days ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 20 days ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire
- 2 months ago - Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - GlobeNewsWire
- 4 months ago - Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
- 4 months ago - Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - GlobeNewsWire
- 5 months ago - Exicure, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting - GlobeNewsWire